Drug Trial Radar · NCT05952089
A Study to Assess the Effect of Danicamtiv on the Drug Levels of Midazolam in Participants With Stable Heart Failure
Last checked: Nov 20, 2026Latest source record: Apr 4, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
13
Actual
Start
Aug 17, 2023
Primary completion
Mar 15, 2024
Study completion Mar 19, 2024
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Jul 19, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is assess the effect of danicamtiv, as an inducer on the drug levels of midazolam in participants with heart failure with reduced ejection fraction (HFrEF).
Conditions
- Heart Failure With Reduced Ejection Fraction
Interventions
DanicamtivDrug
Specified dose on specified days
MidazolamDrug
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum observed plasma concentration (Cmax)Time frame: Up to Day 12
- Area under the plasma concentration time curve from time zero extrapolated to infinite time (AUC[INF])Time frame: Up to Day 12
- Area under the plasma concentration time curve from time zero to the time of the last quantifiable concentration (AUC[0-T])Time frame: Up to Day 12
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Holy Cross Hospital
Fort Lauderdale, Florida
Nature Coast Clinical Research
Inverness, Florida
Jacksonville Center For Clinical Research
Jacksonville, Florida
Research Integrity LLC
Owensboro, Kentucky
Sinai Hospital Of Baltimore
Baltimore, Maryland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.